XML 44 R35.htm IDEA: XBRL DOCUMENT v3.23.1
Merger and Related Transactions - Additional Information (Detail) - ARS Pharma [Member]
$ in Thousands
12 Months Ended
Dec. 31, 2022
USD ($)
Business Acquisition [Line Items]  
Prepaid expense and other assets $ 4,400
Accrued liabilities and other liabilities 12,000
Acquired in-process research and development 1,100
Cash, cash Equivalents, and short-term investments 262,300
Business combination, Intangible assets recognized 0
Business combination, Goodwill recognized 0
Additional Paid-in Capital [Member]  
Business Acquisition [Line Items]  
Business Combination Acquisition Related Costs $ 2,100